This paper investigated the concordance between next generation sequencing (NGS) using the NextDaySeq lung panel on an Ion Torrent and real-time PCR using the Human KRAS, PIK3CA and BRAF Gene Mutations Detection Kits on genotyping calls in non-small cell lung carcinoma (NSCLC) specimens. Genotyping discrepancies were further investigated by additional real-time qPCR assays, Sanger sequencing, and additional NGS.
Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing.
Xu X, Yang Y, Li H, Chen Z, Jiang G, Fei K
Purpose
Conclusion
NGS identified 18 variants not included in the real-time qPCR assay and initially missed 10 variants identified by real-time qPCR. However, all 18 variants not investigated by real-time qPCR were confirmed using other platforms and the 10 variants missed by NGS were found to be present in the initial data but occurred below the variant allele frequency (VAF) cut-off.
Studies (1)
Purpose
This study investigated the concordance of genotyping calls obtained by NGS using the NextDaySeq lung panel on an Ion Torrent and by real-time qPCR using the Human KRAS, PIK3CA and BRAF Gene Mutations Detection Kits in NSCLC specimens. Researchers were blinded when comparing techniologies. Genotyping discrepancies were further investigated by additional real-time qPCR assays (Roche Cobas KRAS and EGFR Mutation Test panels), Sanger sequencing, and/or additional NGS using a custom AmpliSeq panel. Areas with >10% tumor content were selected from 188 resected NSCLC specimens. Although specimen processing details were not provided, the authors state that microdissected fresh specimens were snap-frozen and used when an FFPE specimen was not available. DNA was extracted from five or more 5µm FFPE sections using QIAamp DNA FFPE Tissue Kit and from frozen specimens using QIAamp DNA Tissue Kit. The resultant DNA was stored at -20˚C until use. NGS using the NextDaySeq lung panel on an Ion Torrent achieved >500x coverage in 96.2% of specimens with 96.8% uniformity.
Summary of Findings
Of the 109 mutations identified using the NextDaySeq lung panel, 89 were also identified with real-time qPCR and 18 were not included in the real-time qPCR panel. Additionally, 10 mutations originally identified by qPCR were not found using the NextDaySeq lung panel. Thus, if real-time qPCR was considered the reference method after the initial assay, NGS had a sensitivity of 89.9%, specificity of 97.5%, PPV of 97.8%, and NPV of 88.6%. However, further analysis showed that the 10 mutations originally missed by NGS were in fact detected but at a level below the default VAF cut-off of 1%. Similarly, the two mutations identified by NGS but originally missed by real-time qPCR were present after repeating the initial assay and when investigated using the COBAS real-time qPCR assays. Of the 18 variants identified by NGS but not included in the real-time qPCR panels, the 13 that occurred at a VAF of more than 10% were confirmed by Sanger sequencing but the remaining five which occurred at a VAF of 2.2-7.3% were not detected by Sanger sequencing but were confirmed with the use of AmpliSeq deep sequencing.
Biospecimens
TissueLungPreservation Types
FrozenFormalinDiagnoses
NeoplasticCarcinomaPlatforms
DNANext generation sequencingDNADNA sequencingDNAReal-time qPCRDNASNP assayPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Next generation sequencing Specific Targeted nucleic acid AmpliSeq PanelNextDaySeq Lung panelNext generation sequencing Specific Technology platform Real-time PCRSanger sequencingDNA sequencing Specific Targeted nucleic acid BRAF exons 11 and 15EGFR exons 18, 19, 20, and 21KRAS exons 2 and 3PIK3CA exons 9 and 20Real-time qPCR Specific Targeted nucleic acid Human BRAF Gene Mutations Detection KitHuman KRAS Gene Mutations Detection KitHuman PIK3CA Gene Mutations Detection KitRoche Cobas EGFR Mutation Test panelsRoche Cobas KRAS Mutation Test panels